The postoperative analgesia efficacy of dexamethasone added to bupivacaine versus bupivacaine alone in ultrasound-guided supraclavicular brachial plexus block for upper limb orthopedic surgeries, Ethiopia: An observational prospective cohort study

Kassaw Moges¹, Yilkal Tadesse¹ and Fisiha Fentie²

Abstract

Objectives: To compare the postoperative analgesia efficacy of dexamethasone added to low-dose high-volume bupivacaine in ultrasound-guided supraclavicular brachial plexus block for adult patients who underwent upper limb orthopedic surgeries at Tibebe Ghion Specialized Hospital, Bahir Dar, Ethiopia.

Methods: An observational prospective cohort study was conducted from 1 September 2021 to 30 January 2022. Using a systematic random sampling technique, 56 patients (equal groups of 28 patients) aged 18–60 years scheduled for elective upper limb orthopedic surgeries under supraclavicular block were recruited. According to the discretion of anesthetists’ management plan of supraclavicular block, those patients who received 38 mL of 0.25% bupivacaine with 2 mL (8 mg) dexamethasone as the case group (DB) while those patients who received 40 mL of 0.25% bupivacaine alone as the cohort group (B). Time to first analgesic request, onset of sensory and motor, and motor block duration were analyzed with Student’s t-test whereas pain severity and analgesic consumption were assessed using the Mann–Whitney U test. Categorical variables were analyzed using chi-square test. p-value less than 0.05 considered statistically significant.

Results: Postoperative analgesia had significantly prolonged in the dexamethasone bupivacaine group with a mean duration of 1098.00 ± 195.90 min compared to 464.29 ± 113.75 min in the bupivacaine alone group, p-value < 0.001. Moreover, the dexamethasone bupivacaine group significantly consumed less total tramadol and diclofenac than bupivacaine alone, with a median dose of 0 (0–50) versus 50 (21.25–78.75) mg and 40 (0–50) versus 65 (47.50–77.50) mg, respectively. The median visual analogue scale scores were significantly reduced at 6th, 8th, 12th, and 24th hour in the dexamethasone bupivacaine group.

Conclusion: Dexamethasone added to low-dose high-volume of bupivacaine in supraclavicular brachial plexus block significantly prolonged the duration of analgesia.

Keywords
Analgesia efficacy, bupivacaine, dexamethasone, ultrasound-guided supraclavicular block, upper limb surgeries

Date received: 27 March 2022; accepted: 29 August 2022

Introduction

Pain is a complex sensation difficult to define as well as difficult to assess in appropriate objective manner. The International Association of Pain defines pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage.”¹ Postoperative pain has a probability of progressing...
to chronic pain unless appropriately managed on time. Understanding the pathophysiology of pain, surgical procedures type, and patient factors related to increased pain, such as anxiety and depression are important for adequate control of postoperative pain. Optimal management of postoperative pain is an important part of care of surgical patient, and insufficient control of pain may lead to unwanted effects, such as prolonged recovery, prolonged hospital stay, and chronic pain.

Surgeries on the upper limb have traditionally been done under general anesthesia. Nowadays ultrasound-guided brachial plexus block is a popular approach for upper limb surgeries as an alternative to general anesthesia. From the different approaches to brachial plexus block, the supravacular approach is an easy and appropriate technique for anesthesia and analgesia in surgeries below the shoulder joint and this study evaluated it. It provides greater analgesia, maintains stable intraoperative hemodynamics, reduces the stress response, and decreases anesthetic requirement and benefit for the patients with various cardiorespiratory comorbidities. Moreover, the lack of a consistent protocol among hospitals, including our hospital, on the use of particular analgesic and its effect on patient outcomes throughout hospitals, promoted us to conduct this study.

Supraclavicular brachial plexus block is performed under a variety of local anesthetics to create favorable operative conditions. Of all the local anesthetics, bupivacaine is routinely used for supraclavicular block despite its short duration of action. The use of a perineural catheter is another means of prolonging analgesia, but it is technically more difficult, has a higher risk of migration and infection, and limited resources. Adjuvants such as opioids, neostigmine, clonidine, verapamil, and midazolam were added to local anesthetics, but the results are either inclusive or associated with side effects. Ideally, the adjuvants should not only prolong the duration of analgesia but also cost-effective. Dexamethasone is one of the easily available drugs. Dexamethasone’s mechanism of action to produce analgesia by blocking transmission of nociceptive myelinated c-fibers and suppressing ectopic neuronal discharge. Varieties of local anesthetics to create favorable operative conditions, and a patient with anxiety who needed sedation were included in the study.

Methods

Study design and patients

A hospital-based observational prospective cohort study was conducted at the Tibebe Ghion Specialized Hospital from September 2021 to 30 January 2022. The study comprised 56 orthopedic patients aged 18–60 years who were scheduled for elective upper limb surgeries. The study followed ethical principles and Bahir Dar University, College of Medicine and Health Sciences, Ethical Review Board Committee approved the study to go with written informed consent. The study was retrospectively registered at http://www.researchregistry.com with the Unique Identifying Number (UIN): researchregistry7748. This study followed the EQUATOR (Enhancing the Quality and Transparency Of health Research) criteria from www.strobe.statement.org.

Due to the lack of prior similar studies in the study area, sample size calculation was made based on findings from a literature, taking the mean and variance of first analgesic request time for groups receiving bupivacaine alone and a bupivacaine combined dexamethasone group as 308 ± 109.14 versus 458 ± 205.43, respectively. Then, it was calculated using a mean comparison formula for continuous outcomes with an alpha error of 0.05 at a power of 90%

\[
n_1 = \frac{(\sigma_1^2 + \sigma_2^2)(Z_{alpha/2} + Z_\beta)^2}{(\mu_1 - \mu_2)^2}
\]

where \( \sigma_1 \) is the dexamethasone with bupivacaine group sample variance, \( \sigma_2 \) is the bupivacaine alone group sample variance, \( \mu_1 \) is the mean of dexamethasone with bupivacaine group, \( \mu_2 \) is the mean of bupivacaine alone group, \( \alpha \) is the conventional multiplier for alpha which was taken as 0.05 and making \( Z\alpha = 1.96 \), and \( \beta \) is the power of the study with \( 1 - \beta = 0.90 \) making \( Z_\beta = 1.28 \). Substituting the variables yields the sample size 25

\[
n = \frac{(205.43^2 + (109.14)^2)}{(458 - 308)^2} \times (1.96 + 1.28)^2
\]

\[
n = 25
\]

Using a 1:1 ratio between groups and adding 10% contingency for dropouts, the final sample size of the study became 56 patients. Data were collected from one patient for every three adult patients undergoing upper extremity orthopedic surgeries under supraclavicular block using a systematic sampling technique with a random start after situational analysis from former orthopedic surgery logbook.

This study included all adult patient scheduled for upper limb surgeries under supraclavicular block, the American Society of Anesthesiologists (ASA) status I and II, and between ages of 18 and 60 years. Patients who used local anesthetics other than bupivacaine, addition of another additives, and a patient with anxiety who needed sedation were
not selected for the study. In addition, participants who were not willing to participate in the study and those who wished to quite their participation at any stage of the study were informed to withdraw themselves freely from the study. The study’s outcome variable was duration of pain following surgery which is called postoperative pain. Sociodemographic variables like age and sex, weight, ASA status, vital signs, site and type of surgery, duration of surgery, onset of sensory and motor block, duration of motor block, first analgesic request time, postoperative analgesic consumption, visual analogue scale (VAS), and incidence of complications were the independent variables.

**Study protocols**

All perioperative cares were at the discretion of the assigned anesthetists to each case or other care providers per routine practice and was not influenced or intentionally altered as a result of participation in this study. We the investigators did not involve in the perioperative management of patients. Since our university not yet allowed randomized control trial (RCT), the patients were not randomized for anesthetic management. Because the study site lacked a protocol for the supraclavicular brachial plexus block, some patients received 0.25% of 40 mL bupivacaine alone (B) while others received 2 mL (8 mg) dexamethasone with 38 mL of 0.25% bupivacaine combined with 2 mL (8 mg) dexamethasone or 40 mL of 0.25% bupivacaine alone was administered by the preference of responsible anesthetists after confirming the correct position of 23G size needle and negative aspiration of blood.

**Methods of data collection**

The data collectors observed intraoperative and postoperative condition of the patient during each procedure. All anesthetists, who were performed the block, were anesthesia professional specialists with at least 4 years of experience in conducting anesthesia. Since the study was observational prospective cohort, the responsible anesthetists with independent decision conducted the supraclavicular block. After full drug injection, a trained anesthetist who was not involved in anesthesia administration documented vital signs, onset of sensory, and motor block time. The sensory and motor block time of radial, medial, medial cutaneous, musculocutaneous, and ulnar nerves were evaluated every 5 min for 30 min and then every 1 h after the end of surgery until the block completely worn off. Then, the block was considered successful when analgesia was present in all areas supplied by these major nerves. Each nerve sensory block was assessed by pinprick on a 3-point scale\(^1\) as 2 denoting normal sensation, 1 denoting loss of pinprick sensation, and 0 denoting loss off sensation to light touch. And the degree of motor block was measured using the modified Bromage scale\(^2\) as 3 representing the elbow flexion against gravity, 2 representing the wrist flexion against gravity, 1 representing the finger movement, and 0 representing no motion. Moreover, all vital parameters—including heart rate (HR), mean arterial pressure (MAP), respiratory rate (RR), and SpO\(_2\)—were recorded on the checklist every 5 min for the first 30 min and then every 30 min to the end of surgery\(^3\) from anesthesia monitoring devices. Sociodemographic and other factors were recorded from anesthesia recording sheets and patient’s medical record.

Presence and intensity of pain, first analgesic request time, type and total analgesic need in the first 24 h, and duration of motor block were recorded from the immediate postoperative time by the other trained anesthetist who was not involved in administering anesthesia. On the morning of the procedure, patients were given instructions on how to self-report pain using VAS score which is composed of 10 cm line, with 0 denoting no pain at all and 10 denoting the worst possible pain\(^4\) and the data collector recorded patient self-report. The pain score was assessed at the 1st, 2nd, 4th, 6th, 8th, 12th, and 24th hour after the end of surgery.\(^8\) Adverse effects such as nausea, vomiting, seizure, hypotension, bradycardia, respiratory depression, and allergic reactions were also documented. Patients gave their written informed consent every day. Data completeness and consistency were checked daily.

In the study area, the routine practice of supraclavicular brachial plexus block, some patients received 0.25% of 40 mL bupivacaine combined with 2 mL (8 mg) dexamethasone or 40 mL of 0.25% bupivacaine alone was administered by the preference of responsible anesthetists after confirming the correct position of 23G size needle and negative aspiration of blood.

Ultrasound-guided supraclavicular block preparation and technique. In the study area, the routine practice of supraclavicular block is provided either by 0.25% of 38 mL bupivacaine with 2 mL (8 mg) dexamethasone or 0.25% of 40 mL bupivacaine alone. After preoperative preparation, patients were shifted to the operation room, standard monitoring such as blood pressure cuff, pulse oximetry, and electrocardiogram (ECG) were applied as routine. Baseline vital signs were recorded, and intravenous fluids were administered. Patients were positioned supine with their arms by their sides, the head 30–45° up and rotated to the side opposite to the injection. A cushion was then placed under the ipsilateral shoulder to facilitate the performance of the block. The clavicle and the clavicular head of the sternocleidomastoid muscle were then palpated and the LOGIQ-V2 ultrasound probe was placed in the supraclavicular fossa to visualize first rib, pleura, and brachial plexus near the subclavian artery. The supraclavicular area was then cleaned with disinfectant, and 1–2 cm lateral to the probe, 2–3 mL of 2% lidocaine was used for skin infiltration. Finally, either 38 mL of 0.25% bupivacaine combined with 2 mL (8 mg) dexamethasone or 40 mL of 0.25% bupivacaine alone was administered by the preference of responsible anesthetists after confirming the correct position of 23G size needle and negative aspiration of blood.
Table 1. Demographic parameters, ASA classification, and site, type, and duration of surgery between dexamethasone bupivacaine and bupivacaine alone in adult elective upper limb orthopedic surgery at the Tibebe Ghion Specialized Hospital from 1 September 2021 to 30 January 2022.

| Variables                  | DB (n = 28) | B (n = 28) | p-value |
|----------------------------|-------------|------------|---------|
| Age                        | 36.32 ± 10.38a | 35.57 ± 10.00a | 0.784   |
| Sex                        |             |            |         |
| Male                       | 22 (78.6%)  | 17 (60.7%) | 0.245   |
| Female                     | 11 (21.4%)  | 11 (39.3%) |         |
| Weight (kg)                | 62.07 ± 10.38a | 62.54 ± 9.35a | 0.861   |
| ASA status                 |             |            |         |
| ASA I                      | 20 (71.4%)  | 26 (92.9%) | 0.549   |
| ASA II                     | 8 (28.6%)   | 2 (7.1%)   |         |
| Site of procedure          |             |            |         |
| Hand                       | 1 (3.58%)   | 2 (7.14%)  | 0.706   |
| Forearm                    | 3 (10.71%)  | 4 (14.29%) |         |
| Elbow                      | 3 (10.71%)  | 5 (17.86%) |         |
| Upper arm                  | 21 (75%)    | 17 (60.71%)|         |
| Type of procedure          |             |            |         |
| Tendon repair              | 1 (3.58%)   | 2 (7.14%)  | 0.785   |
| Manipulation               | 2 (7.14%)   | 3 (10.71)  |         |
| K-wire                     | 1 (3.58%)   | 2 (7.14%)  |         |
| ORIF                       | 24 (85.70%) | 21 (75%)   |         |
| Duration of surgery        | 93.36 ± 25.32a | 93.18 ± 24.07a | 0.979   |

DB: dexamethasone bupivacaine; B: bupivacaine; ASA: American Society of Anesthesiologists; ORIF: open reduction and internal fixation.

*p-value ± standard deviation; others in n (%), number (proportion); the independent sample t-test and the chi-square test (χ² test) were used.

Operational definition

Onset of sensory block: the time from study solution injection to loss of sensation to pinprick at all nerve distribution.23

Onset of motor block: the time from study solution injection to paresis at all nerve distribution.15

Duration of motor block: the time from onset of motor block to complete recovery of motor functions.24

Block failure: presence of pinprick sensation in at least one neural distribution and/or need of another anesthetic technique to proceed surgery.7,10,22

Duration of surgery: the time from incision to closure of skin.

First analgesic request time: the initial time patients need pain intervention postoperatively.25,26

Total analgesic consumption: postoperative analgesic drugs given to the patient in 24h.

VAS: pain assessment tool determined by the patient mark their pain intensity on 10 cm long line.12,22

Hypotension: more than 20% decrease in the mean arterial pressure from baseline value.27

Bradycardia: a decrease in HR less than 50 beats/min.9

Nausea and vomiting: when a patient experiences ≥1 episode of either nausea or vomiting in 24h.

Statistical analysis

Data were entered and analyzed using the SPSS version 23 software program. The Shapiro–Wilks and the Kolmogorov–Smirnov tests were used to test normality of the data. The Levene test was used to assess the homogeneity (equality) of variance. The normally distributed data such as the time of the first analgesic request, the onset of sensory and motor block, the duration of motor block, and hemodynamic changes were analyzed using a Student’s t-test. However, for further paired comparison at each time interval, non-normally distributed variables such as total postoperative tramadol and diclofenac doses, number of analgesic requests and VAS measurements were analyzed using a non-parametric Mann–Whitney U test. In addition, the strength of association between categorical variables was assessed using the chi-square statistical test method (χ²-test). Finally, the results then plotted on graph and tables and provided as mean value ± standard deviation for normally distributed variables, a median (interquartile range) for non-normally distributed, and frequencies (percentages) for categorical data. A p-value < 0.05 considered to be statistically significant.

Results

Demographic and perioperative characteristics

A total of 56 patients (28 patients in each group) were finally involved and analyzed without non-response. The entire blocks were considered as successful. The demographic data including age and sex, weight, ASA classification, and site, type and duration of surgery were comparable between the groups, as shown in (Table 1).

Comparison of hemodynamic changes after supraclavicular block

Pulse rate and mean arterial blood pressure at 5, 10, 15, 20, 25, 30, 60, 90, and 120 min were not statistically significant between the bupivacaine alone and dexamethasone bupivacaine groups with p-value > 0.05.

Comparison of characteristics of supraclavicular block and analgesics consumption

The onset of sensory and motor block time in minutes was shorter in dexamethasone bupivacaine group than bupivacaine alone group with a statistically significant difference. Moreover, the duration of motor block and time of first analgesic request in minutes were significantly prolonged, and 24 h total postoperative consumption of analgesic in mg was
Table 2. Supraclavicular brachial plexus block characteristics and analgesics consumption in 24 h between dexamethasone bupivacaine and bupivacaine alone groups in adult elective upper limb orthopedic surgery at the Tibebe Ghion Specialized Hospital from 1 September 2021 to 30 January 2022.

| Variables                      | DB (n = 28)   | B (n = 28)   | p-value |
|--------------------------------|---------------|--------------|---------|
| Onset time of motor block in min | 15.39 ± 3.82  | 18.93 ± 3.87 | 0.001   |
| Onset time of sensory block in min | 11.54 ± 4.32  | 14.39 ± 4.72 | 0.022   |
| Duration time of motor block in min | 778.54 ± 235.50 | 435.39 ± 179.82 | <0.001 |
| Duration of analgesic request in min | 1098.00 ± 195.90 | 464.29 ± 113.75 | <0.001 |
| Number of dose requests in 24 h | 1 (1–1.75)±  | 3 (2.25–4)±  | <0.001 |
| Total dose of tramadol in mg    | 0 (0–50)±     | 50 (21.25–78.75)± | <0.001 |
| Total dose of diclofenac in mg  | 40 (0–50)±    | 65 (47.50–77.50)± | 0.002   |
| Total dose of analgesic in mg   | 50 (41.25–60)±| 95 (76.25–150)± | <0.001 |

DB: dexamethasone bupivacaine; B: bupivacaine.

*Median (IQR); others in mean value ± standard deviation; the independent sample t-test were used.

Table 3. Postoperative pain severity score between dexamethasone bupivacaine and bupivacaine alone groups in adult elective upper limb orthopedic surgery at the Tibebe Ghion Specialized Hospital from 1 September 2021 to 30 January 2022.

| Variables | DB (n = 28) | B (n = 28) | p-value |
|-----------|-------------|------------|---------|
| At 1st hour M (IQR) | 0 (0–0) | 0 (0–0) | 1.000 |
| At 2nd hour M (IQR)  | 0 (0–0) | 0 (0–0) | 1.000 |
| At 4th hour M (IQR)  | 0 (0–0) | 0 (0–0) | 1.000 |
| At 6th hour M (IQR)  | 0 (0–0) | 1 (0–2.75) | <0.001 |
| At 8th hour M (IQR)  | 0 (0–0) | 3 (1–4) | <0.001 |
| At 12th hour M (IQR) | 1.5 (0–3) | 4 (3.25–4) | <0.001 |
| At 24th hour M (IQR) | 2.5 (2–4) | 5 (4–5) | <0.001 |

DB: dexamethasone bupivacaine; B: bupivacaine; M: median; IQR: interquartile range.
The Mann–Whitney U test was used.

Discussion

High volume of local anesthetics used in brachial plexus blocks usually spreads outside the nerve sheath produced complications,$^{13}$ which were seen with the “Landmark” techniques, but ultrasound-guided nerve block obviated these complications.$^5$ Single injection of bupivacaine for supraclavicular brachial plexus block provides good operative conditions but has shorter duration of postoperative analgesia.$^8$ To avoid this limitation, adjuvants have been used, such as steroids.$^8$ Steroids have anti-inflammatory, analgesic, immunosuppressive, and antiemetic properties.$^{25}$ Epidural steroids were for treatment of back pain and sciatica,$^{24}$ but dexamethasone is preferred because of its anti-inflammatory property, about 30 times as potent as hydrocortisone and without any mineralocorticoid activity.$^{15}$ Preoperative oral and intravenous administration of dexamethasone have been shown to reduce overall pain scores and analgesic requirement in the postoperative period.$^{24}$ In this study, we have evaluated the postoperative efficacy of dexamethasone added to low-dose high-volume bupivacaine in supraclavicular brachial plexus block. Age, sex, weight, ASA classification, and site, type, and duration of surgery were comparable in both groups with p-value > 0.05, which were supported by other studies.$^{17,18}$

In the dexamethasone bupivacaine and bupivacaine alone groups, there was a comparable postoperative median pain scores at 1st, 2nd, and 4th hour with a p-value > 0.05, which was equivalent to El.Azzazi et al.'s$^8$ study. The reason for not statistically significant between groups at 1st, 2nd, and 4th hour postoperatively is due to the analgesic effects of perineural administered bupivacaine for supraclavicular block might have been persisted from 3 to 6 h.$^5$ After that, the plasma concentration of bupivacaine wears off. The result was consistent with a randomized double-blinded controlled study done in Egypt,$^6$ in which pain scores at 6th, 8th, 12th, and 24th hour were statistically significant, and Youssef et al.'s study showed that pain scores statistically significant at 6th, 12th, and 24th hour. This resemblance to our research, statistically significant pain scores at 6th, 8th, 12th, and 24th hour, might be related with the wear off analgesic effects

Comparison of postoperative pain severity on VAS score

The postoperative median VAS scores at 1st, 2nd, and 4th hour were comparable between bupivacaine alone and dexamethasone bupivacaine group. However, the postoperative median pain scores at 6th, 8th, 12th, and 24th hour were lower in the dexamethasone bupivacaine group than bupivacaine alone group with a statistically significant difference as shown in Table 3 and Graph 1.

Postoperative complications incidence between groups

No patients developed hypotension, bradycardia, respiratory depression, allergic reaction, and seizure. Nausea and vomiting were not statistically significant difference in between bupivacaine alone group and dexamethasone bupivacaine group as p-value = 0.419.
In the dexamethasone bupivacaine group, the synergetic effects of dexamethasone with bupivacaine continued.

In this study, patients in the dexamethasone bupivacaine group had a significant longer time for the first analgesic request compared to bupivacaine alone group, with mean of $1098.00 \pm 195.90$ versus $464.29 \pm 113.75$ in minutes, respectively, $p$-value < 0.001. The result was in line with El Azzazi et al.'s study found that the mean analgesia duration in the dexamethasone group was $18.45 \pm 2.26$ h, while in the bupivacaine alone group, it was $10.33 \pm 1.54$ h, $p$-value = 0.001. Further our study was supported by Baral et al.'s study in 2019 found that the mean pain-free time longer in the dexamethasone bupivacaine group than bupivacaine alone group with a $p$-value < 0.0001. In contrast, Hoq N and Maruf AA study showed that the first analgesic requirement time in the dexamethasone bupivacaine group was $864.50 \pm 25.19$ min, while it was $455 \pm 17.09$ min in the bupivacaine alone group. The variance in pain perception evaluation and treatment, as well as differences in pain tolerance levels among societies, could be the possible reasons the shorter pain-free time. Genetics, social, and cultural factors, which vary around the world, influenced pain experience.

Our study showed that 24 patients in dexamethasone bupivacaine group and 28 patients in bupivacaine alone group required postoperative analgesic within 24 h. Postoperative total analgesic consumption within 24 h had reduced in the dexamethasone bupivacaine group with median of 50 (41.25–60) mg compared to bupivacaine alone group with median of 95 (76.25–150) mg, $p$-value < 0.001. This matched the findings of Baral and Pathak study, in which the mean total analgesic consumption was $34.2 \pm 10.51$ mg in dexamethasone bupivacaine group and $79.8 \pm 14.35$ mg in bupivacaine alone group. Duration of analgesia had longer in the dexamethasone bupivacaine group than in the bupivacaine alone group, which could explain why our result was similar to those RCT done in 2019. We also found that the median total number of analgesic request within 24 h was 1 (1–1.75) in dexamethasone bupivacaine group, whereas in bupivacaine alone group, it was 3 (2.25–4) with a statistically significant difference, $p$-value < 0.001, which was supported by a study done in India. Regarding to 24 h median total tramadol consumption, the bupivacaine alone group received significantly more doses of tramadol than bupivacaine + dexamethasone group, 50 (21.25–78.75) versus 0 (0–50), respectively, $p$-value < 0.001. In this study, there was also significant difference in total postoperative diclofenac consumption, $p$-value = 0.002.

Our study found that the mean onset of highest sensory block was earlier in the dexamethasone bupivacaine group than bupivacaine alone group, 11.54 ± 4.32 versus 14.39 ± 4.72, respectively, in minutes, $p$-value = 0.022. This was in line with a study done by Rai and Kedareshvara, although the mean time to reach peak sensory level was more rapid than our study result. There was also a statistically significant difference in

**Graph 1.** Comparison of postoperative pain scores at 1st, 2nd, 4th, 6th, 8th, 12th, and 24th hour between dexamethasone bupivacaine and bupivacaine alone groups in adult elective upper limb orthopedic surgery at the Tibebe Ghion Specialized Hospital from 1 September 2021 to 30 January 2022.
onset of motor block between dexamethasone bupivacaine and bupivacaine alone group, 15.39 ± 3.82 versus 18.93 ± 3.87 in minutes, respectively. This was consistent with an Indian study. The duration of motor block was prolonged in dexamethasone bupivacaine group compared to bupivacaine alone group (778.54 ± 235.50 vs 435.39 ± 179.82, respectively) in minutes, p-value < 0.001. This was supported by Parveen S et al.'s study, even though the duration of motor block was shorter than our result.

El Azzazi et al. and Kumar et al. validated our findings by demonstrating that mean hemodynamic changes were comparable between groups, p-value > 0.05. There were no major difficulties in any of the groups. According to our study, overall incidence of nausea and vomiting was 7.1% in the dexamethasone bupivacaine group and 17.9% in bupivacaine alone groups, with no statistically significance differences, p-value = 0.419. The strength of this study is that study participants were homogeneous between the two groups. There was a limitation in our study: because of the study design was observational prospective cohort, it was difficult to control all confounding factors.

Conclusion

Our study showed that perineural dexamethasone added to low-dose high-volume bupivacaine in supraclavicular block for upper limb orthopedic surgeries prolonged the time to the first analgesic request, reduced the level of pain as well as total analgesic consumption. We proposed perineural dexamethasone added to low-dose high-volume bupivacaine to use for upper limb orthopedic surgeries for the quality of early postoperative analgesia with minimal side effects. We suggested a randomized controlled study to be done to avoid biases and determine the exact severity of pain.

Acknowledgements

The authors give special thanks for staff members of Department of Anesthesia, College of Medicine and Health Sciences for helping of data collection.

Author contributions

K.M. contributed to the conception of research protocol, study design, literature review, data collection and extraction, data analysis and interpretation, and drafting manuscript. Y.T. and F.F. contributed to the literature review, data collection and extraction, and review manuscript. All authors have read and approved the manuscript.

Availability of data and materials

All information was presented in the main manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

The ethical approval of this research was given by Bahir Dar University, College of Medicine and Health Sciences, Ethical Review Board Committee with reference no. cmhs/irb/125/13.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

Written informed consent was obtained from all patients before the study.

ORCID iD

Kassaw Moges https://orcid.org/0000-0002-9553-1335

References

1. Kumar A, Shome PK and Nidhi. A comparative study between supraclavicular brachial plexus block with bupivacaine plus dexamethasone and supraclavicular brachial plexus block with bupivacaine alone. JMSCR 2020; 8: 335–356.
2. Traore MM, Leye PA, Doussoumou E, et al. Dexamethasone as an adjuvant in the axillary echoguided block: prospective single-blind, non-randomized study. J Anest Inten Care Med 2019; 9: 55759.
3. Badran MA, Kamaly AM, Abdel Hamid HM, et al. Dexamethasone as a bupivacaine adjuvant for ultrasound-guided interscalene brachial plexus block: a prospective randomized study. Ain Shams J Anesthesiol 2020; 12: 1–10.
4. Koganti C, Hariharan S and Chen D. Low-dose dexamethasone as an adjuvant for prolonging the duration of brachial plexus block with bupivacaine: a prospective randomised controlled study. Caribb Med J. Epub ahead of print 18 May 2021. DOI: 10.48107/CMJ2021.05.001.
5. Rai S and Kedareshvara KS. To compare efficacy of bupivacaine and bupivacaine with dexamethasone for supraclavicular brachial plexus block in patients undergoing upper-limb surgeries: a one-year randomized controlled trial. Indian J Health Sci Biomed Res 2018; 11: 65–69.
6. Joshi A, Meena A, Sunar RC, et al. A comparative study of anesthetic properties of bupivacaine alone and in combination with dexamethasone for supraclavicular brachial plexus block in patients undergoing elective upper limb surgeries. IMJ Health 2018; 4: 260–264.
7. HongB, OhC, Jo Y, et al. The effect of intravenous dexamethasone and dexmedetomidine on analgesia duration of supraclavicular brachial plexus block: a randomized, four-arm, triple-blinded, placebo-controlled trial. J Pers Med 2021; 11: 1–13.
8. El Azzazi HM, El Agamy AE and Mohamed MM. Effect of adding dexamethasone to bupivacaine in ultrasound guided supraclavicular brachial plexus block versus bupivacaine alone for upper limb orthopedic surgery: a comparative study. Egypt J Hosp Med 2018; 71: 3541–3549.
9. Youssef MY, Elsayed SFH, El-Mottalb EAA, et al. Efficacy of adding ketamine, dexamethasone, and epinephrine with bupivacaine in ultrasound-guided supraclavicular brachial plexus block. Res Opin Anesth Intensive Care 2020; 7: 188–196.
10. Badawy Sayed M, Mostafa Abd El-Hameed S and Mohammed Yousef Ahmed E. Comparative study between dexamethasone and fentanyl as an adjuvant to bupivacaine in ultrasound guided supraclavicular brachial plexus block in upper limb surgeries. Al-Azhar Med J 2019; 48: 501–512.

11. Pathak RG, Satkar AP and Khade RN. Supraclavicular brachial plexus block with and without dexamethasone: a comparative study. Int J Sci Res Publ 2012; 2: 1–7.

12. Shaikh MR, Majumdar S, Das A, et al. Role of dexamethasone in supraclavicular brachial plexus block. IOSR J Dent Med Sci 2013; 12: 1–7.

13. Hanumansetty K, Hemalatha S and Gurudatt CL. Effect of dexamethasone as an adjuvant to 0.5% levobupivacaine in supraclavicular brachial plexus block for upper extremity surgeries. Int J Res Med Sci 2017; 5: 1943–1947.

14. Soni S and Gupta SK. Role of dexamethasone in supraclavicular brachial plexus block: a clinical study. Int J Med Res Prof 2018; 4: 273–275.

15. El-Baradey GF and Elshmaa NS. The efficacy of adding dexamethasone, midazolam, or epinephrine to 0.5% bupivacaine in supraclavicular brachial plexus block. Saudi J Anesth 2014; 8: 578–583.

16. Parveen S, Jan M, Taj A, et al. Effect of dexamethasone as an adjuvant with bupivacaine in ultrasound guided single shot supraclavicular brachial plexus block in upper extremity surgeries: a prospective randomized study. Int J Res Med Sci 2017; 5: 2139.

17. Alarasan AK, Agrawal J, Choudhary B, et al. Effect of dexamethasone in low volume supraclavicular brachial plexus block: a double-blinded randomized clinical study. J Anaesthesiol Clin Pharmacol 2016; 32(2): 234–239.

18. Hoq N and Al Maruf A. Dexamethasone added to bupivacaine prolongs the duration of analgesia for supraclavicular brachial plexus block. Bangladesh J Med Sci 2018; 17: 296–301.

19. Inphum P and Witeethep R. A comparison study of 2 mg versus 4 mg of dexamethasone combined with local anesthetic drug in increasing the analgesic duration of a single-shot supraclavicular brachial plexus block. Thai J Anesthesiol 2017; 43: 307–315.

20. Baral PP and Pathak L. A study of dexamethasone as an adjuvant with bupivacaine for supraclavicular brachial plexus block. IOSR J Dent Med Sci 2019; 18: 15–18.

21. Elsayed S, Ahmed FM and Khalifa OY. Hyaluronidase versus adrenaline as an adjuvant to bupivacaine in ultrasound-guided supraclavicular brachial plexus block for upper limb surgeries. Res Opin Anesth Intensive Care 2019; 6: 206–2013.

22. Arjun BK, Chetan L and Nagaraj AS. Comparison of dexamethasone 4 mg and 8 mg as an adjuvant to 0.5% bupivacaine in supraclavicular brachial plexus block for upper limb surgeries: a randomised clinical study. J Evolution Med Dent Sci 2019; 8: 3084–3088.

23. Sane S, Shokouhi S, Golabi P, et al. The effect of dexmedetomidine in combination with bupivacaine on sensory and motor block time and pain score in supraclavicular block. Pain Res Manag 2021; 2021: 8858312.

24. Dar FA, Najar MR and Jan N. Effect of addition of dexamethasone to ropivacaine in supraclavicular brachial plexus block. Indian J Pain 2013; 27: 165–168.

25. Mathew R, Radha KR and Hema VR. Effect of perineural and intravenous dexamethasone on duration of analgesia in supraclavicular brachial plexus block with bupivacaine: a comparative study. Anesth Essays Res 2019; 13(2): 280–283.

26. Aggarwal A and Gandhi N. A prospective randomised study of adjuvants for supraclavicular brachial plexus block: clonidine vs dexamethasone. Ind J Clin Anaesth 2021; 8: 511–514.

27. Lee MJ, Koo DJ and Choi YS. Dexamethasone or dexmedetomidine as local anesthetic adjuvants for ultrasound-guided axillary brachial plexus blocks with nerve stimulation. Korean J Pain 2016; 29: 29–33.